TrialClinical and translational science2023

Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis.

Junying Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.